CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1

Journal of Experimental Medicine

Volumn 199, Issue 10, 2004, Pages 1409-1420

  Lee, Steven P ^a   Brooks, Jill M ^a   Al Jarrah, Hatim ^b   Thomas, Wendy A ^a   Haigh, Tracey A ^a   Taylor, Graham S ^a   Humme, Sibille ^c   Schepers, Aloys ^c   Hammerschmidt, Wolfgang ^c   Yates, John L ^d   Rickinson, Alan B ^a   Blake, Neil W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antigen presentation; Cytotoxic T lymphocytes; EBNA1; Epstein Barr virus

Indexed keywords

ALANINE; ALPHA INTERFERON; CD8 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; GLYCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEOME; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; EPSTEIN BARR VIRUS; GLYCINE ALANINE REPEAT DOMAIN; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOBLASTOID CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; T LYMPHOCYTE SUBPOPULATION; TARGET CELL;

ALANINE; AMINO ACID SEQUENCE; BURKITT LYMPHOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GLYCINE; HERPESVIRUS 4, HUMAN; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE FRAGMENTS; REPETITIVE SEQUENCES, AMINO ACID;

EID: 2542446376     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20040121     Document Type: Article

References (45)

1. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class 1-restricted antigen processing. Annu. Rev. Immunol. 16: 323-358.
2. Koszinowski, U.H., and H. Hengel. 2002. Viral Proteins Counteracting Host Defences. Springer-Verlag, Berlin. 325 pp.
3. Rickinson, A.B., and E. Kieff. 2001. Epstein-Barr virus. In Fields Virology. D.M. Knipe, and P.M. Howley, editors. Lippincott Williams and Wilkins, Philadelphia. 2575-2627.
4. Lee, M.A., M.E. Diamond, and J.L. Yates. 1999. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J. Virol. 73:2974-2982.
5. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P.M. Steigerwald-Mullen, G. Klein, M.G. Kurilla, and M.G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature. 375:685-688.
6. Levitskaya, J., A. Shapiro, A. Leonchiks, A. Ciechanover, and M.G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:12616-12621.
7. Sharipo, A., M. Imreh, A. Leonchiks, S. Imreh, and M.G. Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939-944.
8. Heessen, S., A. Leonchiks, N. Issaeva, A. Sharipo, G. Selivanova, M.G. Masucci, and N.P. Dantuma. 2002. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc. Natl. Acad. Sci. USA. 99:1532-1537.
9. Dantuma, N.P., A. Sharipo, and M.G. Masucci. 2002. Avoiding proteasomal processing: the case of EBNA1. Curr. Top. Microbiol. Immunol. 269:23-36.
10. Trivedi, P., M.G. Masucci, G. Winberg, and G. Klein. 1991. The Epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int. J. Cancer. 48:794-800.
11. Murray, R.J., M.G. Kurilla, J.M. Brooks, W.A. Thomas, M. Rowe, E. Kieff, and A.B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-168.
12. Khanna, R., S.R. Burrows, M.G. Kurilla, C.A. Jacob, I.S. Misko, T.B. Sculley, E. Kieff, and D.J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia - implications for vaccine development. J. Exp. Med. 176:169-176.
13. Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. Steigerwald-Mullen, M.G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 7:791-802.
14. Blake, N., T. Haigh, G. Shaka'a, D. Croom-Carter, and A. Rickinson. 2000. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:7078-7087.
15. Kelly, G., A. Bell, and A. Rickinson. 2002. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098-1104.
16. Humme, S., G. Reisbach, R. Feederle, H.J. Delecluse, K. Bousset, W. Hammerschmidt, and A. Schepers. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA. 100: 10989-10994.
17. + T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J. Exp. Med. 194:1053-1068.
18. Henriquez, N.V., E. Floettmann, M. Salmon, M. Rowe, and A.B. Rickinson. 1999. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J. Immunol. 162:3298-3307.
19. Schultze, J.L., S. Michalak, M.J. Seamon, G. Dranoff, K. Jung, J. Daley, J.C. Delgado, J.G. Gribben, and L.M. Nadler. 1997. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100:2757-2765.
20. Hill, A.B., S.P. Lee, J.S. Haurum, N. Murray, Q.Y. Yao, M. Rowe, N. Signoret, A.B. Rickinson, and A.J. McMichael. 1995. Class I major histocompatibility complex@restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid lines against which they were raised. J. Exp. Med. 181:2221-2228.
21. Tan, L.C., N. Gudgeon, N.E. Annels, P. Hansasuta, C.A. O'Callaghan, S. Rowland-Jones, A.J. McMichael, A.B. Rickinson, and M. Callan. 1999. A re-evaluation of the frequency of CD8(+) T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827-1835.
22. Khanna, R., S.R. Burrows, V. Argaet, and D.J. Moss. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line. Int. Immunol. 6:639-645.
23. Khanna, R., L. Cooper, N. Kienzle, D.J. Moss, S.R. Burrows, and K.K. Khanna. 1997. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 159:5782-5785.
24. Gavioli, R., S. Vertuani, and M.G. Masucci. 2002. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int. J. Cancer. 101:532-538.
25. Fenteany, G., R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268:726-731.
26. Meng, L., R. Mohan, B.H. Kwok, M. Elofsson, N. Sin, and C.M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA. 96:10403-10408.
27. Lee, D.H., and A.L. Goldberg. 1996. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem. 271: 27280-27284.
28. Schubert, U., L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 404:770-774.
29. Reits, E.A., J.C. Vos, M. Gromme, and J. Neefjes. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 404:774-778.
30. Tellam, J., M. Sherritt, S. Thomson, R. Tellam, D.J. Moss, S.R. Burrows, E. Wiertz, and R. Khanna. 2001. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem. 276:33353-33360.
31. Mukherjee, S., P. Trivedi, D.M. Dorfman, G. Klein, and A. Townsend. 1998. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells. J. Exp. Med. 187:445-450.
32. Dantuma, N.P., S. Heessen, K. Lindsten, M. Jellne, and M.G. Masucci. 2000. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc. Natl. Acad. Sci. USA. 97:8381-8385.
33. Valitutti, S., S. Muller, M. Dessing, and A. Lanzavecchia. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1917-1921.
34. Craiu, A., M. Gaczynska, T. Akopian, C.F. Gramm, G. Fenteany, A.L. Goldberg, and K.L. Rock. 1997. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272:13437-13445.
35. Guermonprez, P., L. Saveanu, M. Kleijmeer, J. Davoust, P. Van Endert, and S. Amigorena. 2003. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature. 425:397-402.
36. Houde, M., S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M.F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature. 425:402-406.
37. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 301:1371-1374.
38. + T lymphocytes. J. Exp. Med. 199:459-470.
39. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199:1421-1431.
40. Blake, N.W., A. Moghaddam, P. Rao, A. Kaur, R. Glickman, Y.G. Cho, A. Marchini, T. Haigh, R.P. Johnson, A.B. Rickinson, et al. 1999. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J. Virol. 73:7381-7389.
41. Nikiforow, S., K. Bottomly, G. Miller, and C. Munz. 2003. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77: 12088-12104.
42. Lee, S.P., C.M. Constandinou, W.A. Thomas, D. Croom-Carter, N.W. Blake, P.G. Murray, J. Crocker, and A.B. Rickinson. 1998. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin 10 on Epstein-Barr virus-specific cytotoxic T cell recognition. Blood. 92:1020-1030.
43. Lee, S.P., A.T. Chan, S.T. Cheung, W.A. Thomas, D. Croomcarter, C.W. Dawson, C.H. Tsai, S.F. Leung, P.J. Johnson, and D.P. Huang. 2000. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J. Immunol. 165:573-582.
44. Khanna, R., P. Busson, S.R. Burrows, C. Raffoux, D.J. Moss, J.M. Nicholls, and L. Cooper. 1998. Molecular characterization of antigen-processing function in Nasopharyngeal Carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 58:310-314.
45. Ossevoort, M., B.M. Visser, D.J. van den Wollenberg, E.I. van der Voort, R. Offringa, C.J. Melief, R.E. Toes, and R.C. Hoeben. 2003. Creation of immune "stealth" genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther. 10:2020-2028.